A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

Slides:

Advertisements

Similar presentations

Pulmonary response in sarcoidosis

Advertisements

A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. A stepwise therapeutic approach in severe uncontrolled asthmatic subjects. GINA:

Decimals > Fractions > Percentages

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.

The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined.

Echocardiography view

Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman.

Correlation of excessive reactive oxygen species (ROS) production to clinical disease severity. Correlation of excessive reactive oxygen species (ROS)

Compliance of the respiratory system (Crs) at baseline and 0 h, 1 h and 2 h following lung volume recruitment. a) Absolute Crs in the respiratory muscle.

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Forced expiratory volume in 1 s (FEV1) results in the RECOVER trial.

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

The values for the provoking dose of mannitol to cause a 15% decrease (PD15) in forced expiratory volume in 1 s (FEV1) showing the different levels of.

Survey scores for Partners In Health (PIH-NL), Patient Activation Measure (PAM13-NL), Euroquol-5D3L (EQ-5D3L) and Short Self-Management Ability Scale (SMAS-s)

Bland–Altman plot of slopes of measurement 1 versus 2

A) Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio as a function of age showing individuals with FEV1/FVC ratio less than the.

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.

A) In the presence of Aspergillus fumigatus, local IgA and IgG levels to A. fumigatus are significantly elevated; *: p

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

In vitro quantification of exon skipping associated with 15 premature termination codons using minigenes. In vitro quantification of exon skipping associated.

Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

A white elephant or the elephant in the room

Swimmer plots showing post-nivolumab progression-free survival for the three main drugs studied according to the line of treatment in which they were received.

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to chronic obstructive pulmonary.

Change in lung clearance index (LCI) (mean±sd % change lung turnovers compared with baseline) based on modelled a, b) continuous and c, d) isolated pre-capillary.

Impact of immunosuppressive therapy on pulmonary function, recurrence of diffuse alveolar haemorrhage (DAH) and chest computed tomography (CT) findings.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Most frequent words and phrases based on user comments about the registry. Most frequent words and phrases based on user comments about the registry. Word.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to exacerbation history (intent-to-treat.

The events that lead to airway narrowing and a reduction in forced expiratory volume in 1 s in response to different indirect challenge tests. The events.

Average mean arterial pressure (Pa) during lung volume recruitment (LVR) in (a) the respiratory muscle weakness (RMW) group and (b) the control group.

Systems biology as a tool to improve idiopathic pulmonary fibrosis (IPF) treatment effectiveness. Systems biology as a tool to improve idiopathic pulmonary.

Flow–volume loop analysis

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

Venn diagram showing the overlap between the various spirometric definitions of airway obstruction and respiratory symptoms. **: p

Patients' and partners' experience of anxiety in the Netherlands (NL) and Germany (GE), based on the Generalised Anxiety Disorder-single item questionnaire.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to previous chronic obstructive pulmonary.

Post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio in subjects aged >50 yrs. Post-bronchodilator forced expiratory.

Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on changes in.

Relationship between bronchodilator response of physiological parameters and concentration of interleukin (IL)-8 in epithelial lining fluid (ELF). Relationship.

Receiver operating characteristic (ROC) curves (area under the curve (AUC) (95% CI)) for FACED (forced expiratory volume in 1 s, age, chronic colonisation.

Comparison between prediction equations from Wang et al

Α1-Antitrypsin (AAT) therapy considerations: a) practical difficulties with AAT infusions; b) concerns regarding AAT doses >60 mg·kg−1 per week. α1-Antitrypsin.

Prevalence of air flow obstruction (age-adjusted) by (A) lower limit of normal of forced expiratory ratio versus self-reported doctor diagnosis and (B)

Weekly pneumococcal community-acquired pneumonia incidence rates over 5 years, with delineated school holiday periods by year. a) Year 1 (September 2008–2009).

Physician perspectives on the most useful methods for monitoring α1-antitrypsin deficiency in the clinical trial setting versus clinical practice. Physician.

Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all trials in comparison with only the first two trials.

Scatter plot of body mass index (BMI) versus forced expiratory volume in the first second (FEV1), and linear correlation lines for normal spirometry and.

Percentage of women using snus and/or cigarette smoke during pregnancy based on self-reported time for stopping from those who completed both 18-week and.

Physician perspectives on self-administration of i. v. α1-antitrypsin

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

A) Forced expiratory volume in 1 s (FEV1) and b) 6-min walk test (6MWT) distance by bronchiectasis in any lobe/vascular pruning in the lower lobes groups.

Percentage of culture-positive or PCR-positive sputum samples at stable state and exacerbation in year 1 and year 2 (full cohort, year 1 or year 2). a)

Lung function adjusted for body length and gestational age in male and female premature infants. Lung function adjusted for body length and gestational.

Supplementary Fig.1. The flow of the subjects.

Composition of the most common clusters at the a) onset of the first acute respiratory tract infection (swab A) and b) 3 weeks later (swab B) illustrated.

Scatterplots showing baseline correlation between forced expiratory volume in 1 s (FEV1) % pred and a) COPD Assessment Test (CAT), b) Clinical COPD Questionnaire.

Absolute change in forced expiratory volume in 1 s (FEV1) % pred over time in clinical trials with a) ivacaftor (IVA) in patients with at least one G551D.

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Percentage of positive results by pathogen among study patients with identified pathogens. “Other” includes respiratory viruses, Stenotrophomonas, Prevotella,

Interleukin (IL)-1β and IL-18 in stable chronic obstructive pulmonary disease (COPD) patients. a) IL-1β and IL-18 relative transcript levels in lung tissues.

Study design for ECLIPSE (VX-659 triple combination) and AURORA (VX-445 triple combination) phase 3 studies. Study design for ECLIPSE (VX-659 triple combination)

Comparison of pre- and post-bronchodilator data for spirometric and oscillometric parameters. Comparison of pre- and post-bronchodilator data for spirometric.

Median (95% CI) exhaled nitric oxide fraction (FeNO) at each visit for the two intervention groups. Median (95% CI) exhaled nitric oxide fraction (FeNO)

Geometric mean (95% CI) response dose ratio (RDR) at each visit for the two intervention groups. Geometric mean (95% CI) response dose ratio (RDR) at each.

Presentation transcript:

a) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following eucapnic voluntary hyperpnoea (EVH) challenge before and after 9 weeks of treatment. a) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following eucapnic voluntary hyperpnoea (EVH) challenge before and after 9 weeks of treatment. Data are presented as mean and individual values. #: p<0.05 versus pre-treatment. Anna R. Jackson et al. ERJ Open Res 2018;4:00122-2017 ©2018 by European Respiratory Society